#Switzerland #Rehabilitation #Geneva #Neurotherapeutics #MindMaze

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results

MindMaze Therapeutics, a vanguard in scalable precision neurotherapeutics, has unveiled groundbreaking results from a multi-site program designed to assess home-based rehabilitation efficacy. Presented at the American Congress of Rehabilitation Medicine (ACRM), this study demonstrates that participants engaged in home rehabilitation using MindMotion achieved a remarkable increase in training sessions compared to traditional outpatient therapies.

Key Findings from the Program

The program involved a total of 177 rehabilitation sessions executed by 172 adults diagnosed with various neurological conditions, primarily strokes, over four outpatient sites operated by Vibra Healthcare. The results detailed in the study indicated that the home rehabilitation initiatives increased the total motor-training dose by a stunning factor of three when compared to conventional outpatient therapy. Especially noteworthy was the statistic that 84% of the training was performed independently, showcasing a leap in patient autonomy during recovery.

Further assessments revealed statistically significant enhancements across multiple parameters:

• - Functional Independence (Average +10.4 points on the Barthel Index)
• - Balance Improvement (Average +10.5 points on the Berg Balance Scale)
• - Cognitive Gains (Average +3.4 points on the SLUMS test)
• - Enhanced Mobility (Average reduction of 8.8 seconds on the Timed Up and Go)

Home-Based Therapy

The multi-site quality improvement initiative aimed at evaluating the feasibility of utilizing MindMotion GO technology in home settings. Participants underwent an eight-week training program, which included optional follow-up weeks where home setups were monitored by therapists. The program's adaptive design addresses a significant gap in the rehabilitation spectrum, ensuring that patients maintain momentum in their recovery journey even after exiting the clinical environment.

Over 90% of participants successfully managed to set up their home rehabilitation systems, highlighting the initiative’s feasibility and accessibility. Moreover, around 80% met the minimum required training exposure metrics set at the program's outset, illustrating strong engagement and compliance rates.

Feedback from participants was overwhelmingly positive, as 83.8% recorded favorable satisfaction ratings regarding their overall rehabilitation experience. Patients felt empowered by the independent training, leading to improved recovery outcomes and higher satisfaction levels.

Looking Ahead: MindMotion Lite

MindMaze's upcoming launch of MindMotion Lite, a tablet-based solution scheduled for late 2026, stands to revolutionize home rehabilitation further. This new product is designed to offer the full spectrum of MindMotion GO's neurotherapeutic activities while also requiring fewer hardware components, thereby easing integration into home care practices and expanding accessibility for health providers.

Zach Henderson, CEO of MindMaze Therapeutics, stressed the importance of these advancements in making high-quality neurotherapeutics accessible. He stated, “Our findings not only demonstrate the effectiveness of our technology in improving patient outcomes but also the potential to integrate these therapies seamlessly into homes, thereby bridging the care gap post-clinic.”

The results from the study support the ongoing mission of MindMaze Therapeutics to operationalize high-intensity, neuro-rehabilitation practices across various healthcare landscapes, addressing the growing demand for neurotherapeutics amid a shortage of specialized clinicians.

A comprehensive overview of the study, "High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program," can be accessed at MindMaze Therapeutics.

About MindMaze Therapeutics

MindMaze Therapeutics (SIX: MMTX) stands as a global leader, actively redefining recovery pathways for neurological patients through innovative solutions. The company leverages cutting-edge software, bespoke sensors, and AI-driven analytics to provide a seamless care continuum, from hospital to outpatient settings to home therapies. As a company grounded in extensive clinical validation, MindMaze Therapeutics is poised to lead the way in neurorestorative medicine's future. To learn more, visit MindMaze Therapeutics.